True Freedom Investing LLC Buys New Position in Moderna, Inc. $MRNA

True Freedom Investing LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, HoldingsChannel reports. The fund bought 6,080 shares of the company’s stock, valued at approximately $1,171,000.

Several other institutional investors and hedge funds have also bought and sold shares of MRNA. Western Pacific Wealth Management LP acquired a new position in shares of Moderna during the third quarter worth $29,000. Ramsey Quantitative Systems acquired a new stake in shares of Moderna in the 3rd quarter worth $40,000. Fortitude Family Office LLC boosted its position in shares of Moderna by 53.1% in the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after purchasing an additional 77 shares in the last quarter. MADDEN SECURITIES Corp acquired a new stake in shares of Moderna in the 3rd quarter worth $55,000. Finally, Allied Private Wealth LLC purchased a new position in Moderna during the 2nd quarter worth $30,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Bradesco Corretora raised Moderna to an “outperform” rating in a report on Friday, August 28th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Finally, Evercore boosted their price target on Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $107.10.

Insider Buying and Selling at Moderna

In other news, CFO Jamey Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by insiders.

Moderna Price Performance

NASDAQ MRNA opened at $221.72 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock’s fifty day moving average price is $182.49 and its 200 day moving average price is $86.52. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $254.48. The company has a market cap of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same quarter last year, the business posted ($2.13) EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.